Fam-Trastuzumab Deruxtecan Shows Positive Results for HER2-Positive Breast Cancer with Brain Metastases
Fam-trastuzumab deruxtecan-nxki (Enhertu: AstraZeneca) achieved a 61.6% progression-free survival (PFS) at 1 year in patients with HER2-positive metastatic breast cancer (BC) who have brain metastases (BMs). The results from the phase 3b/4 DESTINY- …